Meeder Asset Management’s Royalty Pharma RPRX Stock Holding History

Meeder Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.39K	Buy	+114	New	+$5.93K	﹤0.01%	795
2024 Q2	–	Sell	-204	Closed	-$6.2K	–	973
2024 Q1	$6.2K	Buy	+204	New	+$6.01K	﹤0.01%	616
2022 Q1	–	Sell	-4	Closed	–	–	2484
2021 Q4	$0	Sell	4 -14,667	-100%	-$570K	﹤0.01%	2101
2021 Q3	$531K	Sell	14,671 -2,028	-12%	-$78.8K	0.03%	411
2021 Q2	$684K	Sell	16,699 -69	-0.4%	-$2.94K	0.03%	366
2021 Q1	$731K	Buy	+16,768	New	+$795K	0.04%	339

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meeder Asset Management's RPRX Position: Q2 2026 in Review

Meeder Asset Management opened a new position in Royalty Pharma (RPRX) in Q2 2026: 114 shares worth $6.39K. The stake represents ﹤0.01% of the portfolio and ranks #795 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in RPRX as recently as Q1 2024.

Meeder Asset Management first reported a position in RPRX in Q1 2021 and has held it in 6 quarters since. The position peaked at $731K in Q1 2021. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Meeder Asset Management held 114 shares of Royalty Pharma worth $6.39K as of Q2 2026.
Royalty Pharma was a new Meeder Asset Management position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #795 holding.
Meeder Asset Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 6 quarters since.
Meeder Asset Management's Royalty Pharma position peaked at $731K in Q1 2021.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.